Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease

被引:48
|
作者
Kotze, Paulo Gustavo [1 ]
Saab, Mansur Paulo [1 ]
Saab, Barbara [1 ]
da Silva Kotze, Lorete Maria [1 ]
Olandoski, Marcia [2 ]
Pinheiro, Lilian Vital [3 ]
Real Martinez, Carlos Augusto [3 ]
Setsuko Ayrizono, Maria de Lourdes [3 ]
Magro, Daniela de Oliveira [3 ]
Rodrigues Coy, Claudio Saddy [3 ]
机构
[1] Catholic Univ Parana, Colorectal Surg Unit, Cajuru Univ Hosp, Rua Bruno Filgueira 369 Cj,1205, BR-80240220 Curitiba, Parana, Brazil
[2] Catholic Univ Parana, Dept Biostat, Rua Imaculada Conceicao 1155, BR-80215901 Curitiba, Parana, Brazil
[3] Campinas State Univ UNICAMP, Colorectal Surg Unit, Rua Tessalia Vieira Camargo 126, BR-13083887 Campinas, SP, Brazil
关键词
Crohn's disease; Postoperative complications; Tumor necrosis factor alpha; Biological products; INFLAMMATORY-BOWEL-DISEASE; ANTI-TNF; FACTOR THERAPY; ANASTOMOTIC COMPLICATIONS; ABDOMINAL-SURGERY; PREOPERATIVE USE; INFLIXIMAB; METAANALYSIS; OUTCOMES; AGENTS;
D O I
10.1007/s10620-016-4400-2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The real impact of anti-tumor necrosis alpha (TNF) therapy in postoperative complications after intestinal resections in Crohn's disease (CD) still needs to be determined. To compare the postoperative complication rates after elective intestinal resections in CD patients, with or without previous exposure to anti-TNF therapy. This was a retrospective and observational study, with elective intestinal resections for CD (emergency procedures were excluded). Patients were allocated in two groups according to preoperative anti-TNF status. Surgical and medical complications were analyzed and subsequently compared between the groups. A total of 123 patients were included (71 with and 52 without preoperative anti-TNF). The groups were considered homogeneous, except for perianal CD, previous azathioprine, and stomas. There was no significant difference between the groups regarding overall surgical complications (32.69% in anti-TNF- vs. 39.44% in anti-TNF+ patients, p = 0.457) or overall medical complications (21.15 vs. 21.13%, respectively, p = 1.000). In univariate analysis, previous steroids, perianal CD, and stomas were considered risk factors for surgical complications, and previous steroids and hypoalbuminemia for medical complications. In multivariate analysis, previous steroids were associated with higher rates of surgical and medical complications, while hypoalbuminemia was associated with higher medical complication rates. There was no influence of the previous use of anti-TNF agents in postoperative surgical and medical complication rates in elective intestinal resections for CD. Previous steroids and hypoalbuminemia were associated with higher complication rates. This was the first case series of the literature describing outcomes in exclusively elective operations.
引用
收藏
页码:456 / 464
页数:9
相关论文
共 50 条
  • [11] Optimizing Screening for Tuberculosis and Hepatitis B Prior to Starting Tumor Necrosis Factor-α Inhibitors in Crohn's Disease
    van der Have, Mike
    Oldenburg, Bas
    Fidder, Herma H.
    Belderbos, Tim D. G.
    Siersema, Peter D.
    van Oijen, Martijn G. H.
    DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (03) : 554 - 563
  • [12] Abdominal Sonographic Changes After Antibody to Tumor Necrosis Factor (Anti-TNF) Alpha Therapy in Crohn's Disease
    Maria Paredes, Jose
    Ripolles, Tomas
    Cortes, Xavier
    Jesus Martinez, Maria
    Barrachina, Maria
    Gomez, Fernando
    Moreno-Osset, Eduardo
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (02) : 404 - 410
  • [13] Short-term outcomes of laparoscopic surgery for Crohn's disease patients treated with anti-tumor necrosis factor alpha agents
    Hata, Tsuyoshi
    Mizushima, Tsunekazu
    Osawa, Hideki
    Takahashi, Hidekazu
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Hata, Taishi
    Takemasa, Ichiro
    Ikenaga, Masakazu
    Nakajima, Kiyokazu
    Yamamoto, Hirofumi
    Murata, Kohei
    Doki, Yuichiro
    Mori, Masaki
    SURGERY TODAY, 2017, 47 (03) : 320 - 327
  • [14] The Role of Oxidative Stress in Anti-tumor Necrosis Factor Antibody Treatment in Crohn's Disease
    Kupcova, V.
    Turecky, L.
    Uhlikova, E.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (30) : 5226 - 5231
  • [15] Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn's Disease
    Thurlapati, Aswani
    Gandu, Siva Santosh Kumar
    Kulkarni, Shreedhar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)
  • [16] A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease
    Papamichael, Konstantinos
    Mantzaris, Gerassimos J.
    Peyrin-Biroulet, Laurent
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (04) : 493 - 501
  • [17] Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention
    Pagnini, Cristiano
    Cominelli, Fabio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [18] The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors
    Fay, Shmuel
    Ungar, Bella
    Paul, Stephane
    Levartovsky, Asaf
    Yavzori, Miri
    Fudim, Ella
    Picard, Orit
    Eliakim, Rami
    Ben-Horin, Shomron
    Roblin, Xavier
    Kopylov, Uri
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (11) : 1924 - 1929
  • [19] Use of the tumor necrosis factor-blockers for Crohn's disease
    Thomson, Alan B. R.
    Gupta, Milli
    Freeman, Hugh J.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (35) : 4823 - 4854
  • [20] Postoperative Morbidity Risks Following Ileocolic Resection for Crohn's Disease Treated With Anti-TNF Alpha Therapy: A Retrospective Study of 360 Patients
    Jouvin, Ingrid
    Lefevre, Jeremie H.
    Creavin, Ben
    Pitel, Sophie
    Chafai, Najim
    Tiret, Emmanuel
    Beaugerie, Laurent
    Parc, Yann
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (02) : 422 - 432